Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes.

OBJECTIVE This study examines the association between oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS Using administrative claims data (2000-2001) from a managed care organization in the Midwestern U.S., this study analyzed 900 enrollees, aged 18 years and over, with type 2 diabetes who were taking oral antihyperglycemic agents both years but who did not use insulin. Nonadherence was defined as a medication possession ratio (MPR) <80%. Multivariate logistic regression analyses were performed where hospitalization in 2001 was regressed on nonadherence to the oral antihyperglycemic drug regimen in 2000, while controlling for nonadherence to drugs for hypertension and dyslipidemia and for hospitalization in 2000, age, sex, intensity of the diabetes drug regimen, and comorbidities. RESULTS The proportion of enrollees who were nonadherent to the antihyperglycemic drug regimen in 2001 was 28.9%, whereas 18.8 and 26.9% were nonadherent to antihypertensive and lipid-modifying drugs, respectively. The increase in the hospitalization rate for 2001 was most apparent where the antihyperglycemic MPR for 2000 dropped to <80%. Enrollees who were nonadherent to oral diabetes medications in 2000 were at higher risk of hospitalization in 2001 (odds ratio 2.53; 95% CI 1.38-4.64), whereas nonadherence to drugs for hypertension and dyslipidemia were not significantly associated with hospitalization. CONCLUSIONS Patients with type 2 diabetes who do not obtain at least 80% of their oral antihyperglycemic medications across 1 year are at a higher risk of hospitalization in the following year.

[1]  T D Koepsell,et al.  A General Method of Compliance Assessment Using Centralized Pharmacy Records: Description and Validation , 1988, Medical care.

[2]  Laurel,et al.  Pharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission , 2002, Medical care.

[3]  E H Wagner,et al.  Effect of improved glycemic control on health care costs and utilization. , 2001, JAMA.

[4]  J. Menzin,et al.  Potential short-term economic benefits of improved glycemic control: a managed care perspective. , 2001, Diabetes care.

[5]  F. Camacho,et al.  Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. , 2003, Clinical therapeutics.

[6]  J L Cavanaugh,et al.  Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. , 1995, The American journal of psychiatry.

[7]  R. Crum,et al.  Depressive symptoms and metabolic control in African-Americans with type 2 diabetes. , 2000, Diabetes care.

[8]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[9]  John D. Voss,et al.  The association between diabetes metabolic control and drug adherence in an indigent population. , 2002, Diabetes care.

[10]  M. Charlson Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: A response , 1993 .

[11]  R. Bauer,et al.  Correlates of Medication Compliance in Non-Insulin-Dependent Diabetes Mellitus , 1987, Southern medical journal.

[12]  R. Rogers,et al.  Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders. , 1998, Journal of forensic sciences.

[13]  C. Rand,et al.  Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. , 1999, Medical care.

[14]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[15]  G. Dailey,et al.  Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. , 2001, Clinical therapeutics.

[16]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[17]  G. Peterson,et al.  Determinants of patient compliance, control, presence of complications, and handicap in non-insulin-dependent diabetes. , 1984, Australian and New Zealand journal of medicine.

[18]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[19]  P. Guillausseau,et al.  Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. , 2003, Diabetes & metabolism.

[20]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[21]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[22]  J. Jollis,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.

[23]  P. Diggle,et al.  Analysis of Longitudinal Data , 2003 .

[24]  J. K. Won,et al.  Effect of value–added utilities on prescription refill compliance and Medicaid health care expenditures–a study of patients with non–insulin–dependent diabetes mellitus , 1993, Journal of clinical pharmacy and therapeutics.

[25]  K. Farmer,et al.  Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. , 1999, Clinical therapeutics.

[26]  C. Sherbourne,et al.  The impact of patient adherence on health outcomes for patients with chronic disease in the medical outcomes study , 1994, Journal of Behavioral Medicine.

[27]  F. Nuttall,et al.  Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. , 1997, Archives of internal medicine.

[28]  V. G. Guillén,et al.  [Validity of 6 indirect methods in the evaluation of compliance to drug treatment of non-insulin dependent diabetes mellitus]. , 1997 .

[29]  COMPARATIVE RESEARCH Predicting Adherence to Prescription Medication Purchase Among HMO Enrollees With Diabetes , 2015 .

[30]  Leonard H. Epstein,et al.  Developmental aspects of health compliance behavior , 1993 .

[31]  P. Donnan,et al.  Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[32]  J. Jollis,et al.  Further evidence concerning the use of a clinical comorbidity index with ICD-9-CM administrative data , 1993 .

[33]  B. Svarstad,et al.  Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. , 2001, Psychiatric services.

[34]  W. Herman,et al.  The intensification of drug therapy for diabetes and its complications: evidence from 2 HMOs. , 2004, The American journal of managed care.